Sarepta Therapeutics - It's Too Early To Get Excited About siRNA Data (NASDAQ:SRPT)

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Sarepta Therapeutics ( SRPT ) stock made a 35% gain yesterday, rising to a value of $34 per share (market cap of $2.5bn), after the company shared the first clinical results from two of its siRNA programs for neuro ...